Gilead Sciences will invest $275m in return for a 49.9% stake as part of a deal that could see it purchase the cancer immunotherapy developer outright.

Gilead Sciences will invest $275m for a 49.9% stake in the UofT and UCSF-linked company as part of a $1.47bn deal to potentially purchase Pionyr outright.

The home care provider has closed a round led by Optum Ventures and backed by Humana and Echo Health Ventures at approximately $136m.

The series C round consisted of $77m in equity funding and $25m in venture debt, with Kaiser Permanente among the participants.

The agricultural product and services provider added $100m to a FedEx-backed round that reportedly values it at $3.5bn.

MassMutual Ventures, Synchrony and Blue Venture Fund all returned as the user authentication platform developer almost doubled its overall funding.

Kaiser Permanente contributed to a round that pushed the total raised by the Stanford-aligned cellular cancer therapy developer to $300m.

Kaiser Permanente contributed to a round that pushed the total raised by the ceullar cancer therapy developer to $300m.

The SoftBank-backed food delivery service hiked its valuation from $13bn to $16bn in a round led by Durable Capital Partners.

The asset management platform developer's series D round included Aflac Global Ventures, Poalim Capital Markets, and existing backers Clal Insurance and SCB Digital Ventures.